By
AstraZeneca said on Monday it would transfer its global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.
Covis Pharma is expected to pay $270 million on completion of the deal and will cover certain ongoing development costs related to the medicines, London-listed AstraZeneca said.